TWI830530B - Method and system for measuring drug response characteristic message power in migraine patients - Google Patents

Abstract

A method for measuring the drug response characteristic information power of migraine patients for measuring the resting state brain waves of a subject's drug response, and the measurement method has previously measured the drug response of a certain number of healthy subjects. The brain's resting state brain waves are used to build a judgment model. A measurement system that stores at least one judgment model. The measurement system is used to detect drug response characteristic information of a subject. The measurement method is to measure the resting state of the brain of a certain number of healthy subjects' drug responses in advance. Brain waves are used to establish the above judgment model, and the above judgment model is compared with the spontaneous activation energy power of at least one characteristic frequency band of the subject's brain resting state brain waves to obtain the subject's drug response characteristic information.

Description

Method and system for measuring drug response characteristic message power in migraine patients

The present invention relates to a method and system for measuring the power of drug response characteristic information for migraine patients, especially for pre-interpretation of the effectiveness of medication for migraine patients.

Migraine is a common neurological condition with complex pathological causes. One of its characteristics is unilateral headache, which also occurs on the forehead, sides, top of the head, back of the head and behind the orbit, and is pulsating and intermittent. Sexual attacks of pain are often accompanied by nausea, vomiting, photophobia, and sensitivity to sound or movement. The pain can be severe, leading to limb weakness, dizziness, and the possibility of behavioral incapacitation. Some migraine patients may experience visual symptoms such as blurred vision in one or both eyes, loss of visual range, flickering light spots or lines, and changes in the shape of objects before or immediately before the onset of pain.

Preventive drug treatment for migraine symptoms is a common treatment method for migraine symptoms. Its advantage is that it is expected to achieve slowdown and appropriate pain control. However, the actual clinical situation is that it takes a certain period of time, for example, three months, to confirm the curative effectiveness of the drug after drug evaluation on the patient. If the patient's pain is not relieved after taking this drug, or the pain cannot be properly controlled, another drug will be administered, and it will take a certain period of time to confirm whether the treatment effect is effective. It is conceivable that What is important is that the therapeutic effect of the drug must be confirmed after a certain period of time, or a period of time after different drugs are administered. The therapeutic effect period will be a long confirmation waiting period for migraine patients. Not only do patients need After a long period of suffering; especially once the patient loses patience or If the doctor's confidence in the patient changes to another hospital for treatment, other doctors will repeat a period of trial and error.

Therefore, how can we provide accurate reference information so that doctors can conduct objective and precise medication assessments without relying on subjective statements after trying the medication with patients? How can we establish a pre-interpretation method and corresponding system to provide doctors with objective data and obtain specific results? Evaluating the response characteristic information of migraine patients to different drugs is the problem to be solved by the present invention.

In view of the above problems, the main purpose of the present invention is to provide a method for measuring the power of drug response characteristic information of migraine patients, by measuring the electroencephalogram and electrooculogram characteristic values of healthy subjects, migraine patients before and after taking medication, etc. , obtain objective and specific data on drug response characteristic values, so that the patient's drug response can be quantitatively predicted.

Another object of the present invention is to provide a power measurement system for drug response characteristic information of migraine patients, for detecting the resting-state drug response characteristic information of the cerebral drug response cortex of a subject.

10:Measurement system

11:Storage unit

12:Measurement unit

13:Display unit

15: Processing unit

16: Comparison unit

17:Network transmission unit

21~25: Steps

31: Occipital bone adhesive patch

33: Measuring electrode

35: straps

Figure 1 is a schematic diagram of the device architecture of a preferred embodiment of the present invention.

Figure 2 is a flow chart of the implementation method of the preferred embodiment of the present invention.

Figure 3 is a schematic diagram of the placement of scalp electrodes during EEG measurement.

Figure 4 is a schematic diagram of the measurement of drug-responsive cortical locations and measurement results according to the present invention, illustrating the measured spontaneous brainwave spectrum and spontaneous frequency band measurement results for the resting-state brain area locations of the drug-responsive group and the non-responder group. difference.

Figure 5 is a bar graph of measurement results of the present invention, illustrating the statistical reliability of using resting-state brainwave characteristics to evaluate drug response characteristics.

Figure 6 is a schematic diagram of the arrangement of the fixation device and electrodes according to the preferred embodiment of the present invention.

The following describes the implementation of the present invention through specific embodiments. Those familiar with the art can easily understand the advantages and effects of the present invention from the content disclosed in this specification.

The structures, proportions, sizes, etc. shown in the drawings attached to this specification are only used to match the disclosure content of the specification and are for the understanding and reading of those familiar with this art. They are not used to limit the conditions for the implementation of the present invention. Any modification of the structure, adjustment of the size or change of the proportional relationship shall also be deemed to be within the scope of the present invention as long as it does not substantially change the technical content.

The first preferred embodiment of the present invention for measuring the power of drug response characteristic information for migraine patients is shown in Figure 1. The migraine patient drug response characteristic information power measurement system 10 includes a storage unit 11, a measurement unit 12, a display unit 13, a processing unit 15, a comparison unit 16, and a network transmission unit 17; wherein the processing unit 15 is signal connected to the above The measurement unit 12 and the comparison unit 16 are signal-connected to the storage unit 11 and the processing unit 15 .

In this case, first, the resting-state electroencephalogram (Neuroscan, Compumedics Ltd) of a certain number of healthy subjects and subjects with migraine was accumulated and measured, and each subject was measured at a sampling frequency of, for example, 500Hz. 5 minutes; participants were instructed to close their eyes but remain awake and relaxed, and not to perform any explicit tasks. Among them, the brain area that will produce significant differences in drug response is defined here as the drug response cortex. The brain wave data emitted by this area can provide subsequent comparison by establishing an appropriate number of maternal sample judgment models.

In order to avoid misjudgments in the judgment model, the above-mentioned subjects in this example must remain awake and in a relaxed state, and cannot consume caffeine or take analgesics before the test. The above-mentioned subjects with migraine disorders exclude (1) overuse Headache medication or use of migraine preventives, (2) regularly or once daily The use of hormones or other drugs, and (3) patients with severe depression or affective disorders; in addition, although the subjects with the aforementioned migraine disorders are allowed to have intermittent headaches, if an acute migraine occurs, or for any reason If migraine medication is used, the EEG recording will be rescheduled.

靜息態，且在步驟22維持以例如500Hz取樣頻率持續記錄至少5分鐘。在建立判斷模型的階段中，量測時的頭皮電極安放位置如圖3所示，是依照傳統的腦電波量測方式，同時量測受測者在靜息態的腦部各區域自發活化功率，並且依據頻率高低分布，供後續進行統計運算。 As shown in step 21 of FIG. 2 , in this embodiment, the measurement unit 12 measures the subject's brain waves through a plurality of brain wave recording patches until the subject's brain is in a certain state.

Resting state, and in step 22, maintain continuous recording at a sampling frequency of, for example, 500 Hz for at least 5 minutes. In the stage of establishing the judgment model, the scalp electrode placement during measurement is shown in Figure 3. It follows the traditional brain wave measurement method and simultaneously measures the spontaneous activation power of various brain regions of the subject in the resting state. , and distributed according to the frequency for subsequent statistical calculations.

Once the subject falls asleep in step 23, the subject will be woken up and the aforementioned steps 21 and 22 will be repeated; and in step 24, the resting state information of the drug response cortex measured by the measurement unit 12 will be passed through the processing unit 15 After filtering, the interference of the electrocardiogram data or electrooculogram data is eliminated, and the spontaneous activation power of at least one characteristic frequency band such as the alpha frequency band (8-13Hz frequency range) is obtained. In the process of establishing the judgment model, the spontaneous activation power of the above-mentioned resting-state brain waves of all migraine patients was tracked and measured before taking the medication and three months after taking the medication, and based on the migraine patients' response to taking specific medications, such as After three months of flunarizine, whether there is significant improvement in symptoms, the patients will be divided into two groups: responders and nonresponders, and the spontaneous activation power of each group will be counted.

Finally, in step 25, the comparison unit 16 is used to compare the spontaneous activation power of the characteristic frequency band in the resting-state brain wave of the cerebral drug response cortex with the judgment model to generate comparison information and output a drug response characteristic. The message is displayed on the display unit 13 and transmitted to the remote database record through, for example, the network transmission unit 17 . In this case, drug response characteristics The message power is for the left and right visual cortices. The results are shown in Figure 4. In the bilateral visual cortex, the alpha power of non-responders is significantly higher than that of responders. The statistical results are shown in Figure 5. It shows that the left visual cortex: responders=66.8±44.5, non-responders=144.9±136.7, P=0.01, the right visual cortex: responders=51.4±37.2, non-responders=122.2±118.6, P=0.01.

Through the above comparison and statistics, it can be found that there is no need for migraine patients to gradually trial and error, and actually take a complete process of medication before discovering that a certain drug is ineffective for this patient; on the contrary, the effects of many drugs can be measured in advance in the brain. By measuring the spontaneous activation power of cortical resting-state brain waves, we can obtain quantifiable drug response characteristic values and obtain reliable scientific data for physicians’ reference. Moreover, as shown in FIG. 6 , because the judgment model according to the present invention can accurately reduce the area that needs to be measured, according to the disclosure of the present invention, it is only necessary to use a fixing device such as an occipital adhesive sheet 31 to connect a pair of visual cortexes. By fixing the measurement electrode 33 on the drug-responsive cortex of the subject, scientific data for reference can be accurately obtained. Of course, as those skilled in the art can easily understand, the above-mentioned occipital bone adhesive patch 31 can also be installed with an elastic sleeve. The above-mentioned strap 35 on the subject's head, or being directly replaced by a strap, does not hinder the implementation of the present invention. Moreover, whether the occipital bone adhesive patch directly uses wires to output electrical signals converted by measurement, or a button battery and an antenna are installed on the occipital bone adhesive patch to output wireless signals, the effects of the present invention can be achieved.

However, the above are only preferred embodiments of the present invention, and cannot be used to limit the scope of the present invention. All simple equivalent changes and modifications made based on the patent scope of the present invention and the content of the invention description should be made. It is still within the scope of the patent of this invention.

21~25: Steps

Claims (7)

A method for measuring the drug response characteristic information power of migraine patients, which is used to measure the cortical resting-state brain waves of a subject's drug response, and the measurement method previously measures the cortical cortical drug response of a certain number of healthy subjects. Resting state brain waves to establish a judgment model; the measurement method includes the following steps: a) Keep the subject awake and in a relaxed state, and measure the brain waves until the subject's brain is in a state of Resting state; b) Measure the resting state brainwave information of the drug-responsive cortex of the subject's brain and record it for at least 5 minutes; c) Filter and process the resting-state information of the drug-responsive cortex to obtain at least one feature The power of spontaneous activation in the frequency band; and d) comparing the power of spontaneous activation in the above characteristic frequency band in response to the cortical resting state information of the drug with the above judgment model to generate a comparison information and output a drug response characteristic message. The measurement method of claim 1, wherein the drug-responsive cortex is directed to the visual cortex. Such as the measurement method of claim 1, wherein the above-mentioned filtering process is to obtain the power of spontaneous activation in the alpha frequency band (8-13Hz frequency range). A power measurement system for drug response characteristic information of migraine patients, which stores at least one judgment model. The above-mentioned measurement system is used to detect the drug response characteristic information of a subject, and measures the drug response of a certain number of healthy subjects in advance. Cortical resting state brain waves are used to establish the above judgment model, and the above judgment model is compared with the spontaneous activation power of at least one characteristic frequency band of the cortical resting state of the subject's drug response to obtain the subject's drug response characteristics. information; the above-mentioned system includes: at least one storage unit for storing the above-mentioned judgment model; a measurement unit for providing the head drug response cortex settings corresponding to the above-mentioned healthy subjects and the measured subjects, and measuring the above-mentioned drug response cortex resting-state brainwaves; a processing unit for connecting to the above-mentioned measurement unit, filtering the resting-state brainwaves of the drug-responsive cortex to obtain the spontaneous activation power of at least one characteristic frequency band; a comparison unit connected To the storage unit and the processing unit, the spontaneous activation power of the characteristic frequency band of the drug response cortex is compared with the judgment model to obtain the drug response characteristic information of the person being measured. The measurement system of claim 4, wherein the measurement unit includes a fixing device and a plurality of measuring electrodes disposed on the fixing device, and the fixing device is used to respectively fix the measuring electrodes to the subject. The cortical locations of the above drug responses. The measurement system of claim 5, wherein the fixation device is an elastic strap that is placed on the head of the subject. Such as the measurement system of claim 5, wherein the above-mentioned fixing device is an occipital bone adhesive patch, and the above-mentioned measurement electrodes are a pair of visual cortex measurement electrodes.

Images